Stage 2 has been successfully completed, and I anticipate that...

Stage 2 has been successfully completed, and I anticipate that we will see the release of results, additional images, and more in February or around that time. This projection is based on the fact that Stage 2 scans were finished at the end of November, and it typically takes a couple of months to unpack and process the data.

Once Stage 2 data is fully unpacked, the next step is to collaborate with the FDA to plan out the validation stage.

While Stage 3 is considered optional, there's an opportunity to run it in parallel with the FDA liaising process. This parallel approach shouldn't impact the overall timeline for bringing our product to market. In fact, it could be highly advantageous because it allows us to gather additional crucial bleed data, which is arguably some of the most valuable information for acute stroke diagnosis. This approach would not only maintain our timeline but also potentially enhance the quality of our data and product.